GLP 3 Retatrutide: What It Is, How It Works, and What We Actually Know in 2026

GLP-3 Retatrutide at a Glance

Trial sources: Jastreboff et al., NEJM 2023; Eli Lilly trial reports. Regulatory and access sources checked September 17, 2026: Lilly's July 23, 2026 results and submission update; FDA's warning about unapproved GLP-1 products.

What Is "GLP-3"? (And Why the Name Is Misleading)

Let's clear this up right away: there is no human hormone called GLP-3.

Your body produces GLP-1 (glucagon-like peptide-1) and GLP-2 (glucagon-like peptide-2). That's it. There is no third one. The "GLP-3" label started circulating on social media and in news headlines as shorthand for a drug that targets three receptors — but it's not a scientific term, and you won't find it in any medical journal or FDA filing.

The drug people are actually talking about is retatrutide, sometimes called "triple-G" or "triple agonist" in clinical literature. Eli Lilly, the company developing it, has never used the term "GLP-3." Neither has the FDA or the New England Journal of Medicine.

So why does this matter? Because if you search for "GLP-3" looking for real information, you'll run into a lot of confusion. Some sites selling unregulated peptides use the term to sound legitimate. Others use it as clickbait. The correct name is retatrutide, and that's what you should look for when evaluating any source.

Quick glossary of terms you'll see online

How Retatrutide Works: The Triple-Agonist Mechanism Explained

To understand why retatrutide is generating so much attention, it helps to see how weight loss medications have evolved over the past few years.

Generation 1 — Single agonist (GLP-1 only): Drugs like semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) target one receptor: GLP-1. This slows your stomach emptying, reduces appetite, and helps regulate blood sugar. It works. Wegovy showed about 15% average weight loss in its pivotal trial (STEP 1). That was a breakthrough.

Generation 2 — Dual agonist (GLP-1 + GIP): Tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss) targets two receptors: GLP-1 and GIP. GIP enhances insulin release and works alongside GLP-1 on appetite signaling. The result was even better — about 21-22% average weight loss in the SURMOUNT-1 trial.

Generation 3 — Triple agonist (GLP-1 + GIP + Glucagon): Retatrutide targets all three. The addition of glucagon is the key differentiator, and it changes the equation in a fundamental way.

How retatrutide's triple-agonist mechanism targets three receptors simultaneously for enhanced weight loss

Here's what each receptor does and why it matters:

The glucagon piece is what makes retatrutide different from everything that came before it. Semaglutide and tirzepatide primarily work by reducing how much you eat. Retatrutide does that and increases how much energy your body uses. It's not just suppressing appetite — it's shifting your metabolism to burn stored fat more aggressively.

This is also why retatrutide shows dramatic results for fatty liver disease. In a Phase 2 substudy published in Nature Medicine (June 2024), the 12mg dose reduced liver fat by 82.4% at 24 weeks. For context, semaglutide achieves about 50% and tirzepatide about 47% over longer timeframes. The glucagon pathway drives fat out of the liver at a rate nothing else has matched.

The trade-off — and there is always a trade-off — is that glucagon agonism can increase heart rate and may contribute to side effects not seen with single or dual agonists. We'll cover those in detail below.

Why Glucagon Is the Breakthrough (and the Risk)

Here's an analogy that might help. Think of weight loss medications as having two levers to pull: "eat less" and "burn more."

Semaglutide pulls the "eat less" lever. It suppresses appetite and slows digestion, so you naturally consume fewer calories. Tirzepatide pulls the same lever harder, with the added help of GIP.

Retatrutide pulls both levers. It suppresses appetite and it tells your body to increase energy expenditure — to actively burn stored fat, particularly in the liver. That's the glucagon piece. Your metabolism speeds up. Your body reaches into its fat stores and converts them to fuel.

This is also why the liver fat results are so dramatic. Glucagon specifically targets hepatic fat metabolism. It tells the liver: process this stored fat, convert it, get it out. No other approved obesity drug has a direct mechanism for this.

The flip side is that glucagon is a powerful hormone. It naturally raises blood sugar (which GLP-1 and GIP counteract in retatrutide's design), it can increase heart rate, and it may contribute to the dysesthesia signal that's emerging in Phase 3. More power, more complexity, more unknowns.

Sources: Jastreboff et al., NEJM 2023; Sanyal et al., Nature Medicine 2024; Coskun et al., Cell Metabolism 2022; PMC review 2025

Clinical Trial Results: What the Data Actually Shows

This is the section that matters most. Not what social media says. Not what peptide sellers claim. What happened in controlled, peer-reviewed clinical trials with real patients.

Phase 2: The Study That Started the Hype (NEJM, 2023)

The Phase 2 trial was published in The New England Journal of Medicine — one of the most respected medical journals in the world. It enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with weight-related conditions) across U.S. sites. Participants were randomized to receive various doses of retatrutide or placebo for 48 weeks, alongside lifestyle counseling.

Source: Jastreboff et al., NEJM 2023 (NCT04881760)

Several things stand out. First, the 12mg group lost an average of 24.2% of their body weight — roughly 58 lbs — in under a year. Second, participants were still losing weight at 48 weeks. They hadn't hit a plateau. The trial simply ended before they stopped losing. That's unusual and significant.

Third, how you start matters. Groups that began at 2mg and escalated slowly had meaningfully fewer side effects than groups that started at 4mg. The weight loss outcomes were nearly identical either way. This validated the "start low, go slow" approach that's now standard in all the Phase 3 trials.

Retatrutide weight loss results from Phase 2 and Phase 3 TRIUMPH trials

Phase 3: TRIUMPH-4 Results (December 2025)

In December 2025, Eli Lilly announced topline results from TRIUMPH-4, the first completed Phase 3 trial for retatrutide. This was a 68-week study of 445 adults with obesity or overweight who also had knee osteoarthritis.

Source: Eli Lilly press release, December 11, 2025; company-reported topline results (NCT05931367). Full peer-reviewed publication pending.

Lilly later reported topline results from TRIUMPH-1, the broader obesity trial, with average weight loss of 28.3% at 80 weeks on 12 mg. That result should not be substituted for the TRIUMPH-4 data above: the trials enrolled different populations, used different durations, and have not yet been compared head-to-head.

A quick note on the two different weight loss numbers. The "efficacy estimand" shows what happened for people who stayed on the drug for the full 68 weeks — it represents what retatrutide can do under ideal conditions. The "treatment-regimen estimand" includes everyone who was randomized, even those who dropped out early. It represents what actually happened in the real study population. The truth for any individual will fall somewhere between these numbers.

Both results are substantial, but they are averages from selected trial populations—not a promise for an individual. For someone starting at 250 lbs, 28.3% would be about 71 lbs, while 28.7% would be about 72 lbs.

The knee osteoarthritis results were also striking. Pain scores dropped by roughly 75% — and more than 1 in 8 people on retatrutide were completely free of knee pain by the end of the trial.

Phase 3: TRANSCEND-T2D-1 Results (May 2026)

In May 2026, Eli Lilly released topline results from TRANSCEND-T2D-1, the first Phase 3 trial for retatrutide in adults with type 2 diabetes. This was a 40-week study using the 12 mg dose.

Source: Eli Lilly press release, May 2026; company-reported topline results (TRANSCEND-T2D-1). Full peer-reviewed publication pending. These results do not constitute FDA approval.

Liver Fat Reduction (Phase 2 Substudy)

A substudy of the Phase 2 trial looked specifically at participants with fatty liver disease (MASLD). The results, published in Nature Medicine in June 2024, showed liver fat reductions that surpassed every other drug studied:

Source: Sanyal et al., Nature Medicine 2024

An 82% reduction in liver fat in just 24 weeks is remarkable. For indirect comparison (different trials, populations, and durations), semaglutide showed approximately 50% reduction over 72 weeks, and tirzepatide approximately 47% at 52 weeks. The glucagon receptor activity in retatrutide appears to be the driver — glucagon specifically promotes fat metabolism in the liver.

What We Know vs. What We Don't (Yet)

This distinction matters. Being honest about uncertainty is part of giving you the complete picture.

Retatrutide vs. Semaglutide vs. Tirzepatide: How They Compare

This is the comparison most people want. Just know upfront: no study has directly compared retatrutide to semaglutide or tirzepatide head-to-head. The numbers below come from different trials with different patient populations, durations, and designs. Treat them as context, not a definitive ranking.

Sources: STEP 1 (NEJM 2021, peer-reviewed); SURMOUNT-1 (NEJM 2022, peer-reviewed); TRIUMPH-1 (Eli Lilly company-reported topline, 2026†). Cross-trial comparison — not equivalent to head-to-head data. †Estimand definitions and trial populations differ across studies.

What this tells us — and what it doesn't: Retatrutide has produced a large average weight-loss result in Lilly's Phase 3 reports. The liver-fat findings are promising but come from a separate Phase 2 substudy. These results do not establish that retatrutide is the right treatment for a particular person.

Retatrutide also had a higher discontinuation rate in the reported TRIUMPH-4 12 mg group (18.2%) and a dysesthesia signal that needs further characterization. The practical reality is that tolerability matters as much as efficacy. For a deeper dive into these differences, see our tirzepatide vs retatrutide comparison.

Tirzepatide may offer the best balance of strong weight loss with manageable tolerability for most people right now. Semaglutide has the longest real-world safety record and the most data across different conditions (heart disease, kidney disease, sleep apnea).

Retatrutide could eventually surpass both — but it's not available, its long-term safety profile is incomplete, and the dysesthesia signal needs more investigation.

Side Effects and Safety: What's Known, What's Uncertain

Every effective medication has side effects. Retatrutide's side effect profile shares a lot in common with other GLP-1 medications — but it also has some signals that are unique and worth understanding.

Retatrutide side effects from the TRIUMPH-4 report. Dysesthesia is also reported in other retatrutide studies and in current Wegovy and Zepbound labels.

Common Side Effects (from TRIUMPH-4 Phase 3)

Source: Eli Lilly press release and medical information portal (medical.lilly.com), December 11, 2025. Dose-specific safety data pending peer-reviewed publication.

The gastrointestinal side effects — nausea, diarrhea, vomiting, constipation — are consistent with what you'd see with any incretin-based therapy. They're dose-dependent (more common at higher doses), usually worst during the dose escalation period, and tend to improve over time. The Phase 2 trial showed clearly that starting at 2mg rather than 4mg roughly halves the rate of these symptoms during the first weeks.

The Dysesthesia Signal: What You Need to Know

This is the side effect that's getting the most attention from analysts and physicians, because it's new.

Dysesthesia is an abnormal sensation of touch. Normal contact with the skin feels unusual — tingly, burning, itchy, or painful. It's not the same as numbness. It's more like your sense of touch is "turned up" or distorted.

In TRIUMPH-4, 20.9% of participants on the 12mg dose reported dysesthesia, compared to just 0.7% on placebo. On the 9mg dose, the rate was 8.8%. This is a significant difference, and it was not observed in the Phase 2 trial — making it a genuinely new finding.

Here's what we know and don't know:

• Most cases were described as mild and did not lead to stopping the drug
• It's not seen with semaglutide or tirzepatide — it may be related to glucagon receptor activation, but this isn't confirmed
• The Phase 2 trial did note "altered or enhanced skin sensation" at lower rates, so it may not be entirely new — just more apparent at scale
• It needs investigation across additional retatrutide studies and longer follow-up

Is it a dealbreaker? That depends on how the data evolves. For now, it's a legitimate concern that warrants monitoring — not panic, but not dismissal either.

Heart Rate Effects

Retatrutide causes a modest increase in resting heart rate of about 5-10 beats per minute, peaking around 24 weeks and then declining. This is similar to what's seen with GLP-1 agonists generally. The Phase 2 trial also noted a small number of cardiac arrhythmia cases.

Discontinuation Rates: The Bigger Picture

The 18.2% discontinuation rate on the 12mg dose is notably higher than what's been seen with semaglutide (~7%) or tirzepatide (~6-7%). But there's important context:

• Discontinuation rates were correlated with baseline BMI — people with lower BMI were more likely to stop. Some stopped due to "perceived excessive weight loss." In other words, the drug worked too well for some participants.
• Among participants with BMI ≥35, the discontinuation rate dropped to about 12%.
• The 9mg dose had a lower discontinuation rate (12.2%) while still producing 26.4% weight loss.

These results show a tradeoff between average weight loss and tolerability; they do not establish a universally optimal dose.

Long-Term Safety: Honestly Unknown

TRIUMPH-1 followed its main population for 80 weeks and a selected group of participants who completed treatment and tolerated their assigned dose for 104 weeks, approximately two years. That extension does not establish two-year safety for every patient or settle rare harms, cardiovascular outcomes, or three- and five-year use. Longer follow-up and dedicated outcomes studies remain important.

Retatrutide Dosage: What Clinical Trials Used

Dose escalation schedule used in retatrutide clinical trials (Phase 2 and Phase 3 TRIUMPH program)

Dose Escalation Schedule (from Clinical Trials)

In both Phase 2 and Phase 3 trials, retatrutide was administered as a once-weekly subcutaneous injection with gradual dose escalation:

Source: NEJM Phase 2 protocol; TRIUMPH-4 trial design (Eli Lilly 2025). Schedules vary by protocol; see trial records for full details.

Key principles from the trials

Lower starting doses were used in some protocols. Phase 2 compared different starting strategies and found better early tolerability with a 2 mg start than with a 4 mg start. This is a description of a research protocol, not a self-dosing recommendation.

Escalation was protocol-controlled. Trial participants increased doses on a study schedule with clinical monitoring; the schedule was not a general prescription.

Dose changes depended on tolerability. Investigators could adjust or stop treatment when participants had side effects. There is no approved retatrutide schedule for patients to follow.

Dose and benefit must be separated. Higher studied doses produced different average results and side-effect rates, but trial data cannot identify the right dose for an individual outside an approved treatment plan.

Maintenance dosing remains uncertain. Lower-dose maintenance strategies are being studied, but there is not an approved maintenance dose or published evidence that supports a self-directed step-down plan.

Why Online Dosage Charts Are Unreliable

If you've seen retatrutide dosage charts on peptide seller websites, understand what you're looking at: marketing material for an unapproved product, often presented without context about the medical supervision, lifestyle counseling, and safety monitoring that accompanied every dose in clinical trials.

Clinical trial participants had regular check-ins with physicians, blood work monitoring, dietary counseling, and the ability to adjust or stop treatment based on side effects. A dosage chart on a website selling unregulated powder doesn't replicate any of that.

Is Retatrutide FDA Approved? When Could It Be Available?

No. Retatrutide is not FDA-approved. It is not available as a routine FDA-approved prescription; it remains an investigational drug. Research access is controlled by clinical-trial protocols and other applicable FDA pathways.

The TRIUMPH Phase 3 Program: All Current Trials

Eli Lilly's TRIUMPH program is one of the most comprehensive Phase 3 programs in obesity drug history, enrolling over 5,800 participants across multiple trials:

For a selected reference to other programs with Phase 3 records, see other obesity drugs in Phase 3.

Sources: ClinicalTrials.gov; Eli Lilly investor relations; Giblin et al., Diabetes Obes Metab 2026 (trial design paper)

Note: Some media reports cite NCT05869903 for TRIUMPH-4; that is actually an orforglipron study (ATTAIN-1). The correct TRIUMPH-4 registration is NCT05931367, per Eli Lilly's own press materials and ClinicalTrials.gov.

Lilly has reported results from TRIUMPH-1 and TRIUMPH-4, while other studies and follow-up remain subject to their individual protocols. ClinicalTrials.gov is the best source for current recruitment and completion status because registry records can change.

What Lilly Has Announced About Timing

• Regulatory submission: Lilly has said it expects to submit a biologics license application in the first quarter of 2027.
• FDA review: No FDA decision date has been announced, and review timing depends on the application and the agency.
• Approval: Approval is not guaranteed; the filing plan is not an approval promise.
• Pharmacy availability: Any launch would depend on approval, labeling, manufacturing, and distribution.

Third-party sales forecasts are not regulatory timelines and should not be used to predict when retatrutide will be available.

Can You Buy GLP-3 Retatrutide? The Legality and Safety Reality

How to identify unsafe retatrutide products and access the drug legally through clinical trials

The FDA has issued explicit warnings about unapproved GLP-1 drugs, including retatrutide, being sold as "research use only" products — often with dosing instructions clearly intended for human use. The FDA states these products are of "unknown quality" and "may be harmful."

The FDA has warned about unapproved retatrutide products marketed for human use. Retatrutide is not an FDA-approved active ingredient eligible for the federal 503A or 503B compounding exemptions, so a website's "compounded" label does not establish that a product is lawful or safe.

What you're actually buying from "research peptide" sites

• A product with no verified purity, potency, or sterility
• No manufacturing oversight by the FDA or any regulatory body
• No recourse if the product harms you
• A potential legal liability (buying unapproved drugs for personal use)
• No medical supervision for dose escalation, side effect monitoring, or drug interactions

Red Flags: How to Spot Unsafe Retatrutide Products

If you see any of the following, you're looking at an illegitimate source:

• "For research use only" — with dosing instructions for human use
• "Not for human consumption" — but sold in injectable form with reconstitution guides
• No verifiable company address, phone number, or pharmacist oversight
• Payment only via cryptocurrency or wire transfer
• Claims of "99% purity" with no independent lab verification
• No mention of FDA status or investigational nature

How to Report Suspicious Products

If you encounter retatrutide being sold illegally, you can report it to FDA MedWatch at fda.gov/medwatch or call 1-800-FDA-1088.

Sources: FDA.gov — "Concerns with Unapproved GLP-1 Drugs Used for Weight Loss"; FDA Warning Letter to GLP-1 Solution, September 9, 2025

How to Access Retatrutide Legally: Finding a Clinical Trial

Clinical-trial enrollment is the established research-access route for retatrutide today. It is not guaranteed, requires meeting the study's criteria, and may involve a placebo or other protocol limits.

Note on expanded access: In rare cases, patients with serious conditions who have exhausted other options may be eligible for expanded access (also called "compassionate use") outside of a clinical trial. This requires a physician's request to the manufacturer and FDA authorization. Eli Lilly has not publicly announced an expanded access program for retatrutide, but it is worth discussing with your doctor if you believe you may qualify.

How Clinical Trials Work (Quick Overview)

Clinical trials are research studies that test whether a drug is safe and effective before it can be approved. As a participant, you typically receive the study drug (or placebo) at no cost, get regular medical monitoring, and contribute to research that could help millions of people. You won't necessarily get the drug — some participants receive a placebo. You'll sign an informed consent form that explains the risks. You'll have regular visits with the study team. And you can withdraw at any time.

How to Find a Retatrutide Trial Near You

What to Ask the Study Coordinator

• Is this trial currently enrolling in my area?
• What are the specific eligibility criteria I need to meet?
• Is there a possibility I'll receive a placebo instead of the drug?
• How often will I need to visit the study site?
• Are there any costs to me (travel, lab work, etc.)?
• What monitoring and support does the trial include?
• How long does the study last?
• Can I continue receiving the drug after the trial ends?

Key ClinicalTrials.gov Numbers for Reference

• TRIUMPH-1 (main obesity): NCT05929066
• TRIUMPH-2 (obesity + T2 diabetes): NCT05929079
• TRIUMPH-3 (obesity + CV disease): NCT05882045
• TRIUMPH-4 (obesity + knee OA): NCT05931367
• TRIUMPH-Outcomes (CV + renal outcomes): NCT06383390

Source: ClinicalTrials.gov; Eli Lilly medical information

What Happens If You Stop? Discontinuation, Maintenance, and Weight Regain

This is a question people don't ask often enough — but it matters enormously.

Retatrutide-specific data on what happens after you stop the drug is limited because the trials measured results while on treatment. But we have strong evidence from the broader GLP-1/GIP drug class, and the pattern is clear: weight regain after stopping is common and significant.

In the STEP 1 extension study for semaglutide, participants who stopped the drug after 68 weeks regained about two-thirds of their lost weight within a year. A similar pattern was seen with tirzepatide in the SURMOUNT-4 trial — participants who switched from tirzepatide to placebo regained a substantial portion of their weight over 36 weeks.

This isn't a failure of the drugs. It reflects the biology of obesity — it's a chronic condition driven by metabolic and hormonal factors that don't change just because you lost weight. Stopping the medication removes the pharmacological support while the underlying biology remains. Your hunger hormones rebound. Your metabolic rate adjusts. The signals that were suppressed come back.

Lower-dose maintenance strategies are being studied, but retatrutide-specific step-down evidence remains limited. Do not infer a maintenance plan from a trial schedule or online dosage chart; any future dosing would depend on an approved label and clinician guidance.

What this means for retatrutide

• Plan for long-term treatment, not a short course
• The 4mg maintenance dose being studied in TRIUMPH could be important — if a lower dose can maintain results with fewer side effects, that changes the cost and tolerability equation significantly
• Lifestyle changes (nutrition, movement, sleep) are genuinely important — not as a replacement for medication, but as a complement that may reduce the dose needed and improve results
• Discuss a long-term plan with your doctor before starting any obesity medication

Sources: Wilding et al., PubMed 2022 (STEP 1 extension); Aronne et al., JAMA 2024 (SURMOUNT-4)

Should You Wait for Retatrutide or Start Treatment Now?

This is the practical question most people reading this page are actually trying to answer. There's no universal right answer, but here's a framework to help you think about it.

Starting an available medication now probably makes more sense if:

• Your BMI is ≥30 (or ≥27 with complications like diabetes, sleep apnea, or joint pain) and your health would benefit from treatment today — not in 2027. Use our BMI calculator to check.
• You're experiencing health complications that get worse with time (uncontrolled blood sugar, worsening knee pain, sleep apnea)
• You respond well to semaglutide or tirzepatide — many people achieve 15-22% weight loss, which is life-changing
• You want a drug with a known long-term safety profile and years of real-world data
• You don't want to wait for something that may be delayed

Watching and waiting might make sense if:

• You've tried semaglutide and tirzepatide without adequate results — retatrutide's triple mechanism may work where dual or single agonists didn't
• You've plateaued on a current GLP-1/GIP medication and need more weight loss
• You have significant fatty liver disease — retatrutide's liver fat data is dramatically superior to anything available
• You're comfortable enrolling in a clinical trial
• Your doctor recommends a watchful approach based on your specific situation

What you should NOT do

The bottom line

Starting treatment now doesn't prevent you from switching to retatrutide later if and when it's approved. A year of effective treatment with an available medication is a year of improved health, reduced risk, and better quality of life that you can't get back by waiting. Explore telehealth providers or check the cheapest GLP-1 options available today.

Talk to your doctor. This is a medical decision that should be made with a clinician who knows your health history — not based on social media hype or fear of missing out.

A Framework for Thinking About Maintenance (Any GLP-1/GIP Drug)

Whether you start treatment now with an available drug or later with retatrutide, the maintenance question will come up eventually. Here's a practical framework:

Duration planning. These medications work as long as you take them. Plan for months to years, not weeks. If you're starting semaglutide or tirzepatide today, don't think of it as a short course — think of it like blood pressure medication for someone with hypertension.

Cost planning. Even with insurance coverage and savings programs, long-term use adds up. Factor this into your decision. Ask your insurer about long-term coverage policies and out-of-pocket caps.

Lifestyle foundation. Medication is the most powerful tool for weight loss, but it works best alongside consistent nutrition, movement, and sleep habits. These habits won't replace the medication's effects, but they may allow a lower maintenance dose and improve your overall health in ways the drug doesn't directly address (strength, cardiovascular fitness, mental health).

Off-ramp strategy. Discuss with your doctor: What's the plan if you want to stop? What monitoring should be in place? What's the threshold for restarting? Having this conversation upfront reduces panic if circumstances change.

Dose optimization. More isn't always better. If 8mg of retatrutide gives you 22% weight loss with manageable side effects, is the extra 6% from 12mg worth the increased nausea and dysesthesia risk? The same logic applies to current drugs. Work with your doctor to find the dose that gives you the best results at a level of side effects you can live with long-term.

What Will Retatrutide Cost? (And What You Can Do About Cost Now)

Because retatrutide is not FDA-approved, there is no official price, savings program, or insurance benefit to quote. Eli Lilly has not announced launch pricing. Any forecast based on other medicines is speculative.

What Current Medications Cost (for context)

Current-medication prices and savings offers change frequently. Verify eligibility, formulation, and current terms directly with the manufacturer, insurer, or licensed prescriber before making a decision.

What Drives Launch Pricing for Obesity Drugs

Efficacy evidence. Lilly has reported 28.3% average weight loss at 80 weeks in TRIUMPH-1, but a trial result does not determine launch price or prove that the medicine will be more valuable for every patient.

Competition. By 2027, the obesity drug market will be more crowded. Novo Nordisk has its own pipeline. Amgen, Pfizer, and Viking Therapeutics are developing competitors. More competition generally pushes prices down.

Insurance coverage. Coverage depends on the medication, indication, plan, and eligibility rules. Medicare's GLP-1 Bridge began July 1, 2026 for eligible participants and specified FDA-approved products; it does not cover investigational retatrutide. Private plans may require prior authorization. Retatrutide coverage would depend on a future FDA indication and payer decisions.

Future manufacturer programs. Lilly may offer savings support if retatrutide is approved, but no retatrutide program or terms have been announced.

What You Can Do About Cost Right Now

If cost is a concern and you're considering weight loss medication today:

• Check manufacturer savings programs. Lilly's Zepbound savings card can reduce costs to as low as $25/month for commercially insured patients. Novo Nordisk has similar programs for Wegovy.
• Ask about compounded semaglutide or tirzepatide only after checking current FDA guidance. Compounding eligibility and shortage status can change; use a licensed provider and do not assume a lower price means equivalent approval, quality, or coverage.
• Explore telehealth platforms that specialize in weight management — many negotiate lower costs and handle insurance authorization.
• Talk to your insurer. Many plans cover obesity medications with proper documentation of BMI and comorbidities. Your doctor can submit prior authorization with supporting medical records.

Conditions Being Studied Beyond Weight Loss

Retatrutide's triple-agonist mechanism means it may have benefits across several obesity-related conditions. Here's what's being studied:

Sources: ClinicalTrials.gov; Eli Lilly investor materials; Nature Medicine 2024

The fatty liver results are arguably the most medically significant finding beyond weight loss. MASLD (metabolic dysfunction-associated steatotic liver disease) affects roughly 1 in 3 adults and is becoming a leading cause of liver transplants. Current treatment options are limited — there's only one recently approved drug (resmetirom) specifically for the liver scarring stage. An 82% reduction in liver fat with retatrutide could potentially address the disease at an earlier, more reversible stage.

The knee osteoarthritis results from TRIUMPH-4 are also clinically meaningful in a way that pure weight loss numbers don't capture. Knee pain affects mobility, sleep, mental health, and independence. A 76% reduction in pain scores — with more than 1 in 8 patients becoming completely pain-free — represents a real quality-of-life improvement that goes beyond what the scale says.

Phase 3 diabetes evidence is now available from TRANSCEND-T2D-1 and TRIUMPH-2. See the study-specific results above. Improvement in A1C and weight does not establish a retatrutide diabetes indication or determine which medicine is appropriate for an individual patient.

The sleep apnea and cardiovascular studies are still ongoing. If retatrutide shows cardiovascular risk reduction (as semaglutide did in the SELECT trial), it would significantly expand its approved uses and insurance coverage.

Frequently Asked Questions

If you're ready to compare GLP-1 telehealth options, our quiz can help → Find My GLP-1

References, Methodology, and Update Log

How This Guide Was Researched

All clinical trial data in this guide comes from one of four source types:

1. Peer-reviewed publications (New England Journal of Medicine, Nature Medicine, JAMA)
2. Official Eli Lilly press releases (via investor.lilly.com and PR Newswire)
3. ClinicalTrials.gov registrations (NCT numbers linked throughout)
4. FDA official communications (warning letters, safety advisories)

We do not cite social media posts, unregulated seller claims, anecdotal reports, or promotional materials from non-clinical sources. When Phase 3 results are described as "topline," we label them as company-reported data that has not yet been published in a peer-reviewed journal.

Weight loss figures throughout this guide use the efficacy estimand (results from participants who remained on treatment) unless otherwise noted, as this is the standard reporting format in obesity research. We also provide treatment-regimen estimand figures where available for full transparency.

Cross-trial comparisons (retatrutide vs. semaglutide vs. tirzepatide) are clearly labeled as indirect comparisons from separate studies with different designs and populations. No head-to-head trial has compared these drugs.

Primary Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526. (NCT04881760)
2. Eli Lilly and Company. "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." Press release. December 11, 2025.
3. Sanyal AJ, Bedossa P, Engel S, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037-2048.
4. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-1564.
5. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48.
6. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Accessed September 17, 2026.
7. U.S. Food and Drug Administration. Warning Letter to GLP-1 Solution. September 9, 2025.
8. ClinicalTrials.gov. Retatrutide studies: NCT05929066 (TRIUMPH-1), NCT05929079 (TRIUMPH-2), NCT05882045 (TRIUMPH-3), NCT05931367 (TRIUMPH-4), NCT06383390 (TRIUMPH-Outcomes), NCT04881760 (Phase 2).
9. Eli Lilly and Company. Retatrutide TRIUMPH-2 and TRIUMPH-3 results and planned Q1 2027 submission. July 23, 2026. Accessed September 17, 2026.
10. Kaur M, Misra A. "The power of three: Retatrutide's role in modern obesity and diabetes therapy." Eur J Pharmacol. 2024.

Update Log

Medical Disclaimer

Affiliate Disclosure

This website may earn commissions from links to FDA-approved medications, telehealth providers, and related health services. We do not link to, promote, or earn commissions from any source selling unapproved retatrutide products. This page contains no affiliate links to retatrutide since it is not available for purchase. Our editorial content is independent of our affiliate relationships. Read our full advertising disclosure.